Major histocompatibility complex class II-transfected tumor cells present endogenous antigen and are potent inducers of tumor-specific immunity
Open Access
- 24 June 1997
- journal article
- research article
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 94 (13) , 6886-6891
Abstract
We have developed an immunotherapy in which tumor cells transfected with syngeneic major histocompatibility complex (MHC) class II genes are cell-based vaccines for the treatment of established tumor and metastatic disease. If this strategy is to be used clinically, convenient methods for generating class II+tumor cells are necessary. Interferon-γ treatment or transduction of the class II transactivator (CIITA) gene induces class II expression but also up-regulates the class II-associated accessory molecules, invariant chain (Ii) and DM. To determine if interferon-γ treatment and CIITA transduction are potential immunotherapies, we assessed the tumorigenicity of sarcoma cells expressing combinations of class II, Ii, and DM. Since we hypothesized that class II-transfected tumor cells not coexpressing Ii and DM present endogenously encoded tumor peptides, we have assessed the transfectants for antigen presentation activity to MHC class II-restricted antigen-specific CD4+T cells. Tumor challenge studies demonstrate that tumor cells expressing class II without coexpression of Ii or Ii plus DM are highly immunogenic and preferentially present endogenous antigens, while tumors coexpressing class II with Ii or Ii plus DM are not effective immunogens. Because tumor rejection correlates with expression of class II without coexpression of Ii and DM, the most efficacious vaccines will express MHC class II without coexpression of Ii and DM and will preferentially present endogenous antigen.Keywords
This publication has 58 references indexed in Scilit:
- Expression of MHC Class II and B7–1 and B7–2 costimulatory molecules accompanies tumor rejection and reduces the metastatic potential of tumor cellsTissue Antigens, 1996
- REGULATION OF MHC CLASS II GENES: Lessons from a DiseaseAnnual Review of Immunology, 1996
- Biological Implications of HLA‐DR Expression in TumoursScandinavian Journal of Immunology, 1995
- Allelic differences affecting invariant chain dependency of MHC class II subunit assemblyImmunity, 1995
- Regulation of MHC Class II Expression by Interferon-γ Mediated by the Transactivator Gene CIITAScience, 1994
- The Biochemistry and Cell Biology of Antigen Processing and PresentationAnnual Review of Immunology, 1993
- Mice lacking the MHC class II-associated invariant chainCell, 1993
- Antigen presentation of hen egg‐white lysozyme but not of ribonuclease A is augmented by the major histocompatibility complex class II‐associated invariant chainEuropean Journal of Immunology, 1991
- A C-terminal signal prevents secretion of luminal ER proteinsCell, 1987
- Immune interferon: a pleiotropic lymphokine with multiple effectsImmunology Today, 1985